

43. (Newly Added) The immunogenic polypeptide of claim 42 linked to a disulfide/amide-forming agent.

44. (Newly Added) The immunogenic polypeptide of claim 42 linked to a thio-ether-forming agent.

45. (Newly Added) The immunogenic polypeptide of claim 40 wherein the amino acid motif is linked to a suitable carrier.

46. (Newly Added) The immunogenic polypeptide of claim 45 wherein the amino acid motif is linked to a disulfide/amide-forming agent.

47. (Newly Added) The immunogenic polypeptide of claim 45 wherein the amino acid motif is linked to a thio-ether-forming agent.

48. (Newly Added) The immunogenic polypeptide of claim 40 further comprising all or a portion of a particle-forming protein.

49. (Newly Added) The immunogenic polypeptide of claim 40 wherein the amino acid sequence motif is fused with an amino acid sequence encoding all or a portion of a particle-forming protein.

50. (Newly Added) The immunogenic polypeptide of claim 40 further comprising a hepatitis C virus subunit antigen wherein the subunit antigen does not comprise an amino acid sequence motif as shown in SEQ ID NO:8.

51. (Newly Added) The immunogenic polypeptide of claim 40 wherein the amino acid sequence motif is fused with an amino acid sequence encoding a hepatitis C virus subunit antigen wherein the amino acid sequence does not comprise the amino acid sequence motif as shown in SEQ ID NO:8.

52. (Newly Added) An immunogenic composition comprising a pharmaceutically